Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 10, 2010, Pages 2183-2187

  Destache, Christopher J ^a   Belgum, Todd ^a   Goede, Michael ^a   Shibata, Annemarie ^a   Belshan, Michael A ^b  

^a CREIGHTON UNIVERSITY   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Efavirenz; HIV 1; Lopinavir; PLGA; Ritonavir

Indexed keywords

EFAVIRENZ; LOPINAVIR; NANOPARTICLE; POLYGLACTIN; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; BAGG ALBINO MOUSE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; EUTHANASIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; PROSPECTIVE STUDY; SINGLE DRUG DOSE; TISSUE; TISSUE LEVEL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMAL STRUCTURES; ANIMALS; ANTI-HIV AGENTS; BENZOXAZINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MONOCYTES; NANOPARTICLES; POLYESTERS; PYRIMIDINONES; RITONAVIR; SERUM; TIME FACTORS;

EID: 77957235800     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq318     Document Type: Article

References (27)

1. Allavena C, Ferre V, Brunet-Francois C et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005; 39: 300-6.
2. Riddler SA, Haubrich R, DiRenzo AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. New Engl J Med 2008; 358: 2095-106.
3. Crowe S, Zhu T, Muller WE. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003; 74: 635-41.
4. Anabwani G, Navario P. Nutrition and HIV/AIDS in sub-Saharan Africa: an overview. Nutrition 2005;21:96-9.
5. Plot P, Bartos M, Ghys PD et al. The global impact of HIV/AIDS. Nature 2001; 410: 968-73.
6. Destache CJ, Belgum T, Christensen K et al. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 2009; 9: 198.
7. Weller DR, Brundage RC, Balfour HH Jr et al. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Anal Technol Biomed Life Sci 2007; 848: 369-73.
8. Gendelman HE, Orenstein JM, Martin MA et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1988; 167: 1428-41.
9. Dou H, Destache CJ, Morehead JR et al. Development of a macrophage-based nanoparticle platform for anti-retroviral drug delivery. Blood 2006; 108: 2827-35.
10. Dou H, Morehead J, Destache CJ et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocytes-derived macrophages. Virology 2007; 358: 148-58.
11. Gagne J-F, Desormeaux A, Perron S et al. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim Biophys Acta 2002; 1558: 198-210.
12. Gorantla S, Dou H, Boska M et al. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol 2006; 80: 1165-74.
13. Kuo Y-C. Loading efficiencyof stavudine on polybutylcyanoacrylate and methmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int J Pharmaceut 2005; 290: 161-72.
14. Mainardes RM, Gremiao MP, Brunetti IL et al. Zidovudine-loaded PLA and PLA-PEG blend nanoparticles: influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 2009; 98: 257-67.
15. Nowacek AS, Miller RL, McMillan J et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 2009; 4: 903-17.
16. Shah LK, Amiji MM. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm Res 2006; 23: 2638-45.
17. Bender AR, von Briesen H, Kreuter J et al. Efficiency of nanoparticles as a carrier system for antiretroviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob Agents Chemother 1996; 40: 1467-71.
18. Chattopadhyay N, Zastre J, Wong HL et al. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 2008; 25: 2262-71.
19. Dybul M, Chun TW, Ward DJ et al. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy. J Infect Dis 2000; 181: 1273-9.
20. Wong JK, Gunthard HF, Havlir DV et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94: 12574-9.
21. Di Mascio M, Srinivasula S, Bhattacharjee A et al. Antiretroviral tissue kinetics: in vivo imaging using positron emission tomography. Antimicrob Agents Chemother 2009; 53: 4086-95.
22. Schrager LK, D'Souza P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. J Am Med Assoc 1998; 280: 67-71.
23. Solas C, Lafeuillade A, Halfon P et al. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47: 238-43.
24. Crowe SM, Mills J, Elbeik T et al. Human immunodeficiency virus-infected monocyte-derived macrophages express surface gp120 and fuse with CD4 lymphoid cells in vitro: a possible mechanism of T lymphocyte depletion in vivo. Clin Immunol Immunopathol 1992; 65: 143-51.
25. Crowe SM, Mills J, Kirihara J et al. Full-length recombinant CD4 and recombinant gp120 inhibit fusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res Hum Retroviruses 1990; 6: 1031-7.
26. Calmy A, Petoumenos K, Lewden C et al. Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts. HIV Med 2007; 8: 171-80.
27. Woodrow KA, Cu Y, Booth CJ et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009; 8: 526-33.